Hikma Pharmaceuticals PLC 2007 AR2
The report highlights Hikma Pharmaceuticals PLC's operational and financial performance for the fiscal year 2007, alongside its corporate social responsibility initiatives. Key achievements include entering the Egyptian market through the acquisition of Alkan Pharma and expanding into the injectable oncology market with the acquisitions of Ribosepharm and Thymoorgan in Germany. In sustainability, the company became a founding member of the UN Global Compact in Jordan and developed group-wide policies on Health & Safety and the Environment. Additionally, Hikma eliminated non-biodegradable packaging materials at its US facility and achieved zero workplace fatalities across its sites.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2007
Type: AR2
Pages: 108
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals PLC's operational and financial performance for the fiscal year 2007, alongside its corporate social responsibility initiatives. Key achievements include entering the Egyptian market through the acquisition of Alkan Pharma and expanding into the injectable oncology market with the acquisitions of Ribosepharm and Thymoorgan in Germany. In sustainability, the company became a founding member of the UN Global Compact in Jordan and developed group-wide policies on Health & Safety and the Environment. Additionally, Hikma eliminated non-biodegradable packaging materials at its US facility and achieved zero workplace fatalities across its sites.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2007
Reporting Period
Jan 1, 2007 - Dec 31, 2007
Fiscal Year
2007
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Workplace Fatalities
Employees